Last 12 months
Inside the activity.
3 purchase rows · 6 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 2 | 0 |
| Jan 2026 | 1 | 0 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 28, 2026 Filed Oct 1, 2026 00:55 UTC |
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund, L.P.Director
RA Capital Nexus Fund II, L.P.Director
RA Capital Nexus Fund III, L.P.Director
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001231919-26-001416 · form4-09302026_080936.xml · derivative · entry 13 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2026-09-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Immediately exercisable. F1 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F2 · ownership.nature: This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. Read SEC document |
| September 28, 2026 Filed Oct 1, 2026 00:55 UTC |
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund, L.P.Director
RA Capital Nexus Fund II, L.P.Director
RA Capital Nexus Fund III, L.P.Director
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $7.89 | $0.00 |
DisclosureSEC source: 0001231919-26-001416 · form4-09302026_080936.xml · derivative · entry 12 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2026-09-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Immediately exercisable. F1 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F2 · ownership.nature: This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. Read SEC document |
| September 28, 2026 Filed Oct 1, 2026 00:55 UTC |
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund, L.P.Director
RA Capital Nexus Fund II, L.P.Director
RA Capital Nexus Fund III, L.P.Director
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001231919-26-001416 · form4-09302026_080936.xml · derivative · entry 11 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2026-09-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Immediately exercisable. F1 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F2 · ownership.nature: This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. Read SEC document |
| September 28, 2026 Filed Oct 1, 2026 00:55 UTC |
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund, L.P.Director
RA Capital Nexus Fund II, L.P.Director
RA Capital Nexus Fund III, L.P.Director
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.46 | $0.00 |
DisclosureSEC source: 0001231919-26-001416 · form4-09302026_080936.xml · derivative · entry 10 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2026-09-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Immediately exercisable. F1 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F2 · ownership.nature: This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. Read SEC document |
| September 28, 2026 Filed Oct 1, 2026 00:55 UTC |
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund, L.P.Director
RA Capital Nexus Fund II, L.P.Director
RA Capital Nexus Fund III, L.P.Director
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
|
Exercise / conversionCommon Stock | 40,000 | $1.29 | $51,600.00 |
DisclosureSEC source: 0001231919-26-001416 · form4-09302026_080936.xml · nonDerivative · entry 4 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 70,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F2 · ownership.nature: This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. Read SEC document |
| September 28, 2026 Filed Oct 1, 2026 00:55 UTC |
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund, L.P.Director
RA Capital Nexus Fund II, L.P.Director
RA Capital Nexus Fund III, L.P.Director
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
|
Exercise / conversionCommon Stock | 10,000 | $7.89 | $78,900.00 |
DisclosureSEC source: 0001231919-26-001416 · form4-09302026_080936.xml · nonDerivative · entry 3 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F2 · ownership.nature: This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. Read SEC document |
| September 28, 2026 Filed Oct 1, 2026 00:55 UTC |
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund, L.P.Director
RA Capital Nexus Fund II, L.P.Director
RA Capital Nexus Fund III, L.P.Director
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
|
Exercise / conversionCommon Stock | 10,000 | $3.00 | $30,000.00 |
DisclosureSEC source: 0001231919-26-001416 · form4-09302026_080936.xml · nonDerivative · entry 2 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F2 · ownership.nature: This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. Read SEC document |
| September 28, 2026 Filed Oct 1, 2026 00:55 UTC |
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund, L.P.Director
RA Capital Nexus Fund II, L.P.Director
RA Capital Nexus Fund III, L.P.Director
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
|
Exercise / conversionCommon Stock | 10,000 | $3.46 | $34,600.00 |
DisclosureSEC source: 0001231919-26-001416 · form4-09302026_080936.xml · nonDerivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F2 · ownership.nature: This option was granted to Andrew Levin pursuant to the Issuer's non-employee director compensation policy. Under Dr. Levin's arrangement with the Adviser, Dr. Levin held the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:15 UTC |
Thomas Stephen BasilDirector
|
SaleCommon Stock | 100,000 | $13.67 | $1,366,820.00 |
DisclosureSEC source: 0001193125-26-394357 · ownership.xml · nonDerivative · entry 1 Thomas Stephen Basil · CIK 0002027962 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 467,969 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2026. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.3800 to $14.3400, inclusive. The reporting person undertakes to provide the staff of the Securities and Exchange Commission, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 413,312 shares of the issuer's common stock, par value $0.0001 per share, distributed by Sera Medicines, LLC to certain of its limited partners, including the reporting person, for no consideration in a pro-rata in-kind distribution. Read SEC document |
| June 29, 2026 Filed Jun 30, 2026 23:50 UTC |
Brennan AoifeDirector · President and CEO
|
SaleCommon Stock | 30,902 | $13.17 | $406,979.34 |
DisclosureSEC source: 0001193125-26-291131 · ownership.xml · nonDerivative · entry 2 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,731 F3 · kind: The sale reported on this Form 4 was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.02 to $13.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 21:45 UTC |
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund, L.P.Director
RA Capital Nexus Fund II, L.P.Director
RA Capital Nexus Fund III, L.P.Director
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
|
GrantStock Option (Right to Buy) · Derivative | 70,284 | $0.00 Strike: $13.36 | $0.00 |
DisclosureSEC source: 0001231919-26-000722 · form4-07012026_090743.xml · derivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 70,284 Underlying: Common Stock · 70,284 shares Expires 2036-06-29 F1 · derivative.exercise_date: The shares underlying the option vest in equal monthly installments from June 29, 2026 (the "Vesting Commencement Date") until the third anniversary of the Vesting Commencement Date, subject to Ms. Celebi's continued service through such date. F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F3 · ownership.nature: Under Ms. Celebi's arrangement with the Adviser, Ms. Celebi holds the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Ms. Celebi is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 20:30 UTC |
Celebi Breanna MaurineDirector
|
GrantStock Option (Right to Buy) · Derivative | 70,284 | $0.00 Strike: $13.36 | $0.00 |
DisclosureSEC source: 0001193125-26-292640 · ownership.xml · derivative · entry 1 Celebi Breanna Maurine · CIK 0002137903 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,284 Underlying: Common Stock · 70,284 shares Expires 2036-06-29 F1 · derivative.exercise_date: The shares underlying the option vest in equal monthly installments from June 29, 2026 (the "Vesting Commencement Date") until the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through such date. F2 · ownership.direct: Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying common stock. Read SEC document |
| June 27, 2026 Filed Jun 30, 2026 23:50 UTC |
Brennan AoifeDirector · President and CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 68,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-291131 · ownership.xml · derivative · entry 3 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,500 Underlying: Common Stock · 68,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: The RSUs were granted on June 27, 2024 (the "Grant Date") and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service. F6 · derivative.expiration_date: The RSUs were granted on June 27, 2024 (the "Grant Date") and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service. Read SEC document |
| June 27, 2026 Filed Jun 30, 2026 23:50 UTC |
Brennan AoifeDirector · President and CEO
|
Exercise / conversionCommon Stock | 68,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-291131 · ownership.xml · nonDerivative · entry 1 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock F2 · balance_after: Total includes an additional 1,751 shares acquired through the Company's Employee Stock Purchase Plan. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 22:26 UTC |
Dunn JudithDirector
|
GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $10.55 | $0.00 |
DisclosureSEC source: 0001193125-26-262270 · ownership.xml · derivative · entry 1 Dunn Judith · CIK 0001811904 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-06-04 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 22:28 UTC |
Thomas Stephen BasilDirector
|
GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $10.55 | $0.00 |
DisclosureSEC source: 0001193125-26-262273 · ownership.xml · derivative · entry 1 Thomas Stephen Basil · CIK 0002027962 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-06-04 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 18:34 UTC |
Cumbo AlexanderDirector
|
GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $10.55 | $0.00 |
DisclosureSEC source: 0001193125-26-262281 · ownership.xml · derivative · entry 1 Cumbo Alexander · CIK 0001685994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-06-04 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 18:37 UTC |
WILLIAMS DOUGLAS EDirector
|
GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $10.55 | $0.00 |
DisclosureSEC source: 0001193125-26-262287 · ownership.xml · derivative · entry 1 WILLIAMS DOUGLAS E · CIK 0001184847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-06-04 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 22:57 UTC |
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund, L.P.Director
RA Capital Nexus Fund II, L.P.Director
RA Capital Nexus Fund III, L.P.Director
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
|
GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $10.55 | $0.00 |
DisclosureSEC source: 0001231919-26-000610 · form4-06082026_100640.xml · derivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnotes Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-06-04 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 5, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to Dr. Andrew Levin's continuous service through such date. F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. F3 · ownership.nature: Under Dr. Levin's arrangement with the Adviser, Dr. Levin holds the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account. Dr. Levin is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 22:39 UTC |
Drapkin Kimberlee CDirector
|
GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $10.55 | $0.00 |
DisclosureSEC source: 0001193125-26-262290 · ownership.xml · derivative · entry 1 Drapkin Kimberlee C · CIK 0001340881 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-06-04 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 22:42 UTC |
Levin Andrew DavidDirector
|
GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $10.55 | $0.00 |
DisclosureSEC source: 0001193125-26-262292 · ownership.xml · derivative · entry 1 Levin Andrew David · CIK 0001867539 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-06-04 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date. F2 · ownership.direct: Under the reporting person's arrangement with RA Capital Management, L.P. (the "Adviser"), the reporting person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The reporting person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account to the Adviser. The reporting person therefore disclaims beneficial ownership of the stock option and underlying common stock. Read SEC document |
| April 29, 2026 Filed Apr 29, 2026 22:46 UTC |
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund, L.P.Director
RA Capital Nexus Fund II, L.P.Director
RA Capital Nexus Fund III, L.P.Director · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
|
GrantPre-Funded Warrants (Right to Buy) · Derivative | 2,106,000 | $9.50 Strike: $0.00 | $20,006,789.40 |
DisclosureSEC source: 0001231919-26-000429 · form4-04292026_100401.xml · derivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director · 10% owner Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 22,546,000 Underlying: Common Stock · 2,106,000 shares Expires not disclosed F1 · derivative.exercise_date: The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrant if it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 33.0% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise. F1 · derivative.expiration_date: The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrant if it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 33.0% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise. F2 · ownership.nature: These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Fund and the Nexus Fund III collectively own approximately 75% of the outstanding equity interests of Sera Medicines, LLC ("Sera"). Accordingly, each of the Fund, the Nexus Fund III and the Adviser may be deemed to beneficially own the securities held by Sera. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:05 UTC |
Thomas Stephen BasilDirector
|
SaleCommon Stock | 16,313 | $7.01 | $114,288.88 |
DisclosureSEC source: 0001193125-26-082533 · ownership.xml · nonDerivative · entry 2 Thomas Stephen Basil · CIK 0002027962 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,657 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 14, 2025. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.0000 to $7.0400, inclusive. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 21:05 UTC |
Thomas Stephen BasilDirector
|
SaleCommon Stock | 33,687 | $7.00 | $235,963.96 |
DisclosureSEC source: 0001193125-26-082533 · ownership.xml · nonDerivative · entry 1 Thomas Stephen Basil · CIK 0002027962 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 170,970 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 14, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.0000 to $7.0600, inclusive. The reporting person undertakes to provide the staff of the Securities and Exchange Commission, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) of this Form 4. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 21:05 UTC |
Thomas Stephen BasilDirector
|
SaleCommon Stock | 10,000 | $5.81 | $58,141.00 |
DisclosureSEC source: 0001193125-26-054568 · ownership.xml · nonDerivative · entry 2 Thomas Stephen Basil · CIK 0002027962 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 204,657 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 14, 2025. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.6200 to $6.1200, inclusive. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:05 UTC |
Thomas Stephen BasilDirector
|
SaleCommon Stock | 90,000 | $5.23 | $470,988.00 |
DisclosureSEC source: 0001193125-26-054568 · ownership.xml · nonDerivative · entry 1 Thomas Stephen Basil · CIK 0002027962 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 214,657 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 14, 2025. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.2212 to $5.2481, inclusive. The reporting person undertakes to provide the staff of the Securities and Exchange Commission, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) of this Form 4. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 16:05 UTC |
ALTSCHULLER SusanChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 142,500 | $0.00 Strike: $3.81 | $0.00 |
DisclosureSEC source: 0001193125-26-007665 · ownership.xml · derivative · entry 1 ALTSCHULLER Susan · CIK 0001817988 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,500 Underlying: Common Stock · 142,500 shares Expires 2036-01-05 F1 · derivative.exercise_date: This option was granted on January 6, 2026 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through January 6, 2030, subject to the Reporting Person's continued service. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 16:05 UTC |
Wilson Perrin MeganChief Business Officer
|
GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $3.81 | $0.00 |
DisclosureSEC source: 0001193125-26-007667 · ownership.xml · derivative · entry 1 Wilson Perrin Megan · CIK 0002074091 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2036-01-05 F1 · derivative.exercise_date: This option was granted on January 6, 2026 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through January 6, 2030, subject to the Reporting Person's continued service. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:05 UTC |
Brennan AoifeDirector · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 700,000 | $0.00 Strike: $3.81 | $0.00 |
DisclosureSEC source: 0001193125-26-007670 · ownership.xml · derivative · entry 1 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2036-01-05 F1 · derivative.exercise_date: This option was granted on January 6, 2026 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through January 6, 2030, subject to the Reporting Person's continued service. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 16:05 UTC |
Driscoll CindySenior Vice President, Finance
|
GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $3.81 | $0.00 |
DisclosureSEC source: 0001193125-26-007662 · ownership.xml · derivative · entry 1 Driscoll Cindy · CIK 0001741269 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2036-01-05 F1 · derivative.exercise_date: This option was granted on January 6, 2026 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through January 6, 2030, subject to the Reporting Person's continued service. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:55 UTC |
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund, L.P.Director
RA Capital Nexus Fund II, L.P.Director
RA Capital Nexus Fund III, L.P.Director · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
|
PurchaseCommon Stock | 7,111 | $3.50 | $24,888.50 |
DisclosureSEC source: 0001231919-26-000018 · form4-01072026_090137.xml · nonDerivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director · 10% owner Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 3,403,429 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.495 to $3.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Fund and the Nexus Fund III collectively own approximately 75% of the outstanding equity interests of Sera Medicines, LLC ("Sera"). Accordingly, each of the Fund, the Nexus Fund III and the Adviser may be deemed to beneficially own the securities held by Sera. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 00:55 UTC |
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund, L.P.Director
RA Capital Nexus Fund II, L.P.Director
RA Capital Nexus Fund III, L.P.Director · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
|
PurchaseCommon Stock | 101,462 | $2.86 | $290,181.32 |
DisclosureSEC source: 0001231919-25-000616 · form4-12162025_121255.xml · nonDerivative · entry 3 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director · 10% owner Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 3,396,318 F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.32 to $3.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Fund and the Nexus Fund III collectively own approximately 75% of the outstanding equity interests of Sera Medicines, LLC ("Sera"). Accordingly, each of the Fund, the Nexus Fund III and the Adviser may be deemed to beneficially own the securities held by Sera. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| December 11, 2025 Filed Dec 16, 2025 00:55 UTC |
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund, L.P.Director
RA Capital Nexus Fund II, L.P.Director
RA Capital Nexus Fund III, L.P.Director · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
|
GrantPre-Funded Warrants (Right to Buy) · Derivative | 20,440,000 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001231919-25-000616 · form4-12162025_121255.xml · derivative · entry 9 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director · 10% owner Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 20,440,000 Underlying: Common Stock · 20,440,000 shares Expires not disclosed F1 · kind: On December 11, 2025, RA Capital Healthcare Fund, L.P. (the "Fund") entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, for no additional consideration, 20,440,000 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 20,440,000 shares of the Issuer's Common Stock at an exercise price of $0.0001 per share. F1 · price: On December 11, 2025, RA Capital Healthcare Fund, L.P. (the "Fund") entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, for no additional consideration, 20,440,000 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 20,440,000 shares of the Issuer's Common Stock at an exercise price of $0.0001 per share. F11 · derivative.exercise_date: The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrant if it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 33.0% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise. F11 · derivative.expiration_date: The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrant if it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 33.0% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise. F2 · ownership.nature: These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Fund and the Nexus Fund III collectively own approximately 75% of the outstanding equity interests of Sera Medicines, LLC ("Sera"). Accordingly, each of the Fund, the Nexus Fund III and the Adviser may be deemed to beneficially own the securities held by Sera. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| December 11, 2025 Filed Dec 16, 2025 00:55 UTC |
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund, L.P.Director
RA Capital Nexus Fund II, L.P.Director
RA Capital Nexus Fund III, L.P.Director · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
|
PurchaseCommon Stock | 213,099 | $2.18 | $464,555.82 |
DisclosureSEC source: 0001231919-25-000616 · form4-12162025_121255.xml · nonDerivative · entry 2 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director · 10% owner Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 3,294,856 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.11 to $2.20 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Fund and the Nexus Fund III collectively own approximately 75% of the outstanding equity interests of Sera Medicines, LLC ("Sera"). Accordingly, each of the Fund, the Nexus Fund III and the Adviser may be deemed to beneficially own the securities held by Sera. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| December 11, 2025 Filed Dec 16, 2025 00:55 UTC |
RA CAPITAL MANAGEMENT, L.P.Director · 10% owner
RA Capital Healthcare Fund LPDirector · 10% owner
RA Capital Nexus Fund, L.P.Director
RA Capital Nexus Fund II, L.P.Director
RA Capital Nexus Fund III, L.P.Director · 10% owner
Kolchinsky PeterDirector · 10% owner
Shah Rajeev M.Director · 10% owner
|
Disposition to issuerCommon Stock | 20,440,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001231919-25-000616 · form4-12162025_121255.xml · nonDerivative · entry 1 RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director · 10% owner Kolchinsky Peter · CIK 0001384859 · Director · 10% owner Shah Rajeev M. · CIK 0001619841 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 3,081,757 F1 · kind: On December 11, 2025, RA Capital Healthcare Fund, L.P. (the "Fund") entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, for no additional consideration, 20,440,000 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 20,440,000 shares of the Issuer's Common Stock at an exercise price of $0.0001 per share. F2 · ownership.nature: These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Fund and the Nexus Fund III collectively own approximately 75% of the outstanding equity interests of Sera Medicines, LLC ("Sera"). Accordingly, each of the Fund, the Nexus Fund III and the Adviser may be deemed to beneficially own the securities held by Sera. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| October 01, 2025 Filed Oct 1, 2025 17:52 UTC |
ALTSCHULLER SusanChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 600,000 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001193125-25-227099 · ownership.xml · derivative · entry 1 ALTSCHULLER Susan · CIK 0001817988 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires 2035-09-30 F1 · derivative.exercise_date: This option was granted on October 1, 2025 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date, and the remainder are scheduled to vest in 36 equal monthly installments through October 1, 2029, subject to the Reporting Person's continued service. Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 20:15 UTC |
Thomas Stephen BasilDirector
|
GrantCommon Stock | 100,375 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-106563 · ownership.xml · nonDerivative · entry 1 Thomas Stephen Basil · CIK 0002027962 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 304,657 F1 · shares: On June 27, 2024, the reporting person was granted restricted stock units ("RSUs") to acquire a total of 100,375 shares of common stock that vested based on the achievement of certain performance-based milestones and subject to continuous service. On August 7, 2025, the milestones were deemed to be achieved, resulting in the vesting of the RSUs as to all 100,375 shares. Read SEC document |
| June 30, 2025 Filed Jul 1, 2025 20:37 UTC |
Brennan AoifeDirector · President and CEO
|
SaleCommon Stock | 20,618 | $1.22 | $25,153.96 |
DisclosureSEC source: 0000950170-25-092284 · ownership.xml · nonDerivative · entry 2 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,132 F2 · kind: The sale reported on this Form 4 was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $1.20 to $1.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. Read SEC document |
| June 27, 2025 Filed Jul 1, 2025 20:32 UTC |
Thomas Stephen BasilDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 25,094 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-092273 · ownership.xml · derivative · entry 2 Thomas Stephen Basil · CIK 0002027962 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,094 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs were granted on June 27, 2024 and vested as to 50% of the shares on January 1, 2025, vested as to 25% of the shares on March 27, 2025 and vested as to the remaining 25% of the shares on June 27, 2025, subject to the Reporting Person's continued service. F3 · derivative.expiration_date: The RSUs were granted on June 27, 2024 and vested as to 50% of the shares on January 1, 2025, vested as to 25% of the shares on March 27, 2025 and vested as to the remaining 25% of the shares on June 27, 2025, subject to the Reporting Person's continued service. Read SEC document |
| June 27, 2025 Filed Jul 1, 2025 20:32 UTC |
Thomas Stephen BasilDirector
|
Exercise / conversionCommon Stock | 25,094 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-092273 · ownership.xml · nonDerivative · entry 1 Thomas Stephen Basil · CIK 0002027962 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock. Read SEC document |
| June 27, 2025 Filed Jul 1, 2025 20:37 UTC |
Brennan AoifeDirector · President and CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 68,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-092284 · ownership.xml · derivative · entry 3 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 206,250 Underlying: Common Stock · 68,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: The RSUs were granted on June 27, 2024 (the "Grant Date") and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service. F5 · derivative.expiration_date: The RSUs were granted on June 27, 2024 (the "Grant Date") and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service. Read SEC document |
| June 27, 2025 Filed Jul 1, 2025 20:37 UTC |
Brennan AoifeDirector · President and CEO
|
Exercise / conversionCommon Stock | 68,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-092284 · ownership.xml · nonDerivative · entry 1 Brennan Aoife · CIK 0001714563 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock. Read SEC document |
| June 20, 2025 Filed Jun 20, 2025 20:20 UTC |
Pimblett EmilySVP, Finance & CAO
|
SaleCommon Stock | 1,242 | $1.24 | $1,540.08 |
DisclosureSEC source: 0000950170-25-088524 · ownership.xml · nonDerivative · entry 2 Pimblett Emily · CIK 0001969365 · SVP, Finance & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,888 F2 · kind: The sale reported on this Form 4 was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on April 27, 2024 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 20:20 UTC |
Pimblett EmilySVP, Finance & CAO
|
Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-088524 · ownership.xml · derivative · entry 3 Pimblett Emily · CIK 0001969365 · SVP, Finance & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The shares subject to this RSU shall vest at a rate of 1/8th of the total number of shares on the three-month anniversary of March 18, 2024 (the "March 2024 Vesting Commencement Date") and 1/8th of the total number of shares each three-month anniversary of the March 2024 Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the two-year anniversary of the March 2024 Vesting Commencement Date. F4 · derivative.expiration_date: The shares subject to this RSU shall vest at a rate of 1/8th of the total number of shares on the three-month anniversary of March 18, 2024 (the "March 2024 Vesting Commencement Date") and 1/8th of the total number of shares each three-month anniversary of the March 2024 Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the two-year anniversary of the March 2024 Vesting Commencement Date. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 20:20 UTC |
Pimblett EmilySVP, Finance & CAO
|
Exercise / conversionCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-088524 · ownership.xml · nonDerivative · entry 1 Pimblett Emily · CIK 0001969365 · SVP, Finance & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock. Read SEC document |
| June 17, 2025 Filed Jun 20, 2025 16:20 UTC |
Driscoll CindySenior Vice President, Finance
|
GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0000950170-25-088525 · ownership.xml · derivative · entry 1 Driscoll Cindy · CIK 0001741269 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2035-06-16 F1 · derivative.exercise_date: This option was granted on June 17, 2025 (the "Grant Date"). The shares underlying the option are scheduled to vest with respect to 25% of the shares on the first anniversary of the Grant Date and the remainder are scheduled to vest in 36 equal monthly installments through June 17, 2029, subject to the Reporting Person's continued service. Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 20:11 UTC |
Dunn JudithDirector
|
GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0000950170-25-082323 · ownership.xml · derivative · entry 1 Dunn Judith · CIK 0001811904 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-06-03 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 4, 2026 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date. Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 20:10 UTC |
Thomas Stephen BasilDirector
|
GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0000950170-25-082320 · ownership.xml · derivative · entry 1 Thomas Stephen Basil · CIK 0002027962 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-06-03 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 4, 2026 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date. Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 16:11 UTC |
Cumbo AlexanderDirector
|
GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0000950170-25-082324 · ownership.xml · derivative · entry 1 Cumbo Alexander · CIK 0001685994 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-06-03 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 4, 2026 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date. Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 16:11 UTC |
WILLIAMS DOUGLAS EDirector
|
GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0000950170-25-082322 · ownership.xml · derivative · entry 1 WILLIAMS DOUGLAS E · CIK 0001184847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-06-03 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 4, 2026 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.